Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Andrew Obenshain net worth and biography

Andrew Obenshain Biography and Net Worth

Insider of bluebird bio

Andrew Obenshain has served as head of Europe since 2016. He was most recently at Shire in Paris, France where he was the general manager of France and Benelux overseeing a portfolio including seven rare disease products. Prior to Shire, Andrew spent eight years at Genzyme and Sanofi holding roles of increasing responsibility in business development, marketing and global commercial operations. Mr. Obenshain received his MBA from Northwestern University’s Kellogg School of Management, and his B.A. in genetics, cell and developmental biology from Dartmouth College.

What is Andrew Obenshain's net worth?: The estimated net worth of Andrew Obenshain is at least $159,052.00 as of December 10th, 2024. Mr. Obenshain owns 18,712 shares of bluebird bio stock worth more than $159,052 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Obenshain may own. Additionally, Mr. Obenshain receives an annual salary of $1,040,000.00 as Insider at bluebird bio. Learn More about Andrew Obenshain's net worth.
How old is Andrew Obenshain?: Mr. Obenshain is currently 50 years old. There are 3 older executives and no younger executives at bluebird bio. Learn More on Andrew Obenshain's age.
What is Andrew Obenshain's salary?: As the Insider of bluebird bio, Inc., Mr. Obenshain earns $1,040,000.00 per year. Learn More on Andrew Obenshain's salary.
How do I contact Andrew Obenshain?: The corporate mailing address for Mr. Obenshain and other bluebird bio executives is 60 BINNEY STREET, CAMBRIDGE MA, 02142. bluebird bio can also be reached via phone at (339) 499-9300 and via email at [email protected]. Learn More on Andrew Obenshain's contact information.
Has Andrew Obenshain been buying or selling shares of bluebird bio?: Within the last three months, Andrew Obenshain has sold $403.20 in bluebird bio stock. Most recently, Andrew Obenshain sold 48 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $8.40, for a transaction totalling $403.20. Following the completion of the sale, the chief executive officer now directly owns 18,712 shares of the company's stock, valued at $157,180.80. Learn More on Andrew Obenshain's trading history.
Who are bluebird bio's active insiders?: bluebird bio's insider roster includes Jason Cole (Insider), David Davidson (Insider), Nick Leschly (CEO), Andrew Obenshain (Insider), and Jessica Whitten (CAO). Learn More on bluebird bio's active insiders.
Are insiders buying or selling shares of bluebird bio?: During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 463 shares worth more than $9,849.60. The most recent insider tranaction occured on December, 10th when CEO Andrew Obenshain sold 48 shares worth more than $403.20. Insiders at bluebird bio own 1.4% of the company. Learn More about insider trades at bluebird bio.
Information on this page was last updated on 12/10/2024.

Andrew Obenshain Insider Trading History at bluebird bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Sell	48	$8.40	$403.20	18,712
2/5/2024	Sell	93	$18.00	$1,674.00	14,304
1/5/2024	Sell	158	$28.60	$4,518.80	14,398
8/10/2023	Sell	846	$70.80	$59,896.80	14,597
1/11/2023	Sell	158	$156.00	$24,648.00	12,134
11/4/2022	Sell	63	$128.20	$8,076.60	12,293
8/4/2022	Sell	1,090	$87.80	$95,702.00	12,356
1/10/2022	Sell	152	$187.20	$28,454.40
12/7/2021	Sell	41	$203.60	$8,347.60
6/4/2021	Sell	25	$615.00	$15,375.00	1,979
5/3/2021	Sell	1	$603.00	$603.00	2,005

Andrew Obenshain Buying and Selling Activity at bluebird bio

bluebird bio Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Today's Range

Now: $8.50

$7.94

$9.80

50 Day Range

MA: $8.53

$5.89

$14.73

2 Week Range

Now: $8.50

$5.80

$38.40

Volume

899,239 shs

Average Volume

398,183 shs

Market Capitalization

$82.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Missed Nvidia? Buy Elon Musk’s “Silent Partner”

From Brownstone Research | Ad

So please click here to see the details because a lot of people could get rich.

Andrew Obenshain Biography and Net Worth

What is Andrew Obenshain's net worth?

How old is Andrew Obenshain?

What is Andrew Obenshain's salary?

How do I contact Andrew Obenshain?

Has Andrew Obenshain been buying or selling shares of bluebird bio?

Who are bluebird bio's active insiders?

Are insiders buying or selling shares of bluebird bio?